Clinical trial
Study of the Optimal Protocol for Methotrexate and Adalimumab Combination…
NCT00420927 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00420927 |
|---|---|
| Title | Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis |
| Official title | A Multicenter, Randomized, Double-Period, Double - Blind Study to Determine the Optimal Protocol for Treatment Initiation With Methotrexate and Adalimumab Combination Therapy in Patients With Early Rheumatoid Arthritis (OPTIMA) |
| Acronym | OPTIMA |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Biological, Drug |
| Interventions | adalimumab, methotrexate, placebo |
| Enrollment | 1,032 |
| Start date | Dec 1, 2006 |
| Primary completion | Jul 1, 2010 |
| Completion | Jul 1, 2010 |
| First posted | Jan 11, 2007 |
| Last update posted | Apr 18, 2012 |
| Countries | Argentina, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Hungary, Mexico, Netherlands, New Zealand and 9 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: